Peter Francis Net Worth

What's Peter Francis's mailing address?

Peter's mailing address filed with the SEC is C/O BENITEC BIOPHARMA INC., 3940 TRUST WAY, HAYWARD, CA, 94545.

Insiders trading at Benitec Biopharma Inc

Over the last 4 years, insiders at Benitec Biopharma Inc have traded over $0 worth of Benitec Biopharma Inc stock and bought 409,597 units worth $1,496,765 . The most active insiders traders include Steven Michael Oliveira, J Kevin Buchi és Edward F Smith. On average, Benitec Biopharma Inc executives and independent directors trade stock every 278 days with the average trade being worth of $1,152,330. The most recent stock trade was executed by J Kevin Buchi on 11 August 2023, trading 51,813 units of BNTC stock currently worth $437,302.

What does Benitec Biopharma Inc do?

benitec biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases. our transformational technology, ddrnai, targets and ‘turns off’ specific genes related to disease, providing lasting treatment and potentially cure with a single dose. compared to traditional approaches to rna intereference, ddrnai is easier to deliver, safer to us, more targeted and more efficient. benitec has a pipeline of in-house and partnered drug development programs based on ddrnai, including hepatitis c and b and cancer-associated pain. ddrnai has the potential to silence genes related to thousands of human diseases and is protected by over 40 global patents. the technology is available from benitec under a variety of licence options.

Benitec Biopharma Inc executives and stock owners

Benitec Biopharma Inc executives and other stock owners filed with the SEC include:

• Dr. Jerel A. Banks M.D., Ph.D.,
  CEO & Exec. Chairman
• Megan Joan Boston BComm, CA, Dip., GAICD,
  Exec. Director
• Dr. Claudia Kloth,
  Sr. VP of Manufacturing
• Dr. Craig Lewis,
  Chief Medical Adviser
• Dr. Michael Graham,
  Head of Discovery & Founding Scientist
• Bryan Dulhunty,
  Chief Financial Officer
• Edward F Smith,
  Director
• Megan Boston,
  Executive Director
• Jerel A. Banks,
  Chief Executive Officer
• Peter Francis,
  Director
• Steven Michael Oliveira,
  10% owner
• J Kevin Buchi,
  Director